Targeted deletion of the murine apobec-1 complementation factor (acf) gene results in embryonic lethality by Blanc, Valerie et al.




Targeted deletion of the murine apobec-1
complementation factor (acf ) gene results in
embryonic lethality
Valerie Blanc
Washington University School of Medicine
Jeffrey O. Henderson
Washington University School of Medicine
Elizabeth P. Newberry
Washington University School of Medicine
Susan Kennedy
Washington University School of Medicine
Jianyang Luo
Washington University School of Medicine
See next page for additional authors
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Blanc, Valerie; Henderson, Jeffrey O.; Newberry, Elizabeth P.; Kennedy, Susan; Luo, Jianyang; and Davidson, Nicholas O., ,"Targeted




Valerie Blanc, Jeffrey O. Henderson, Elizabeth P. Newberry, Susan Kennedy, Jianyang Luo, and Nicholas O.
Davidson
This open access publication is available at Digital Commons@Becker: http://digitalcommons.wustl.edu/open_access_pubs/2296
  
10.1128/MCB.25.16.7260-7269.2005. 
2005, 25(16):7260. DOI:Mol. Cell. Biol. 
Susan Kennedy, Jianyang Luo and Nicholas O. Davidson
Valerie Blanc, Jeffrey O. Henderson, Elizabeth P. Newberry,
 
Results in Embryonic Lethality
) GeneacfComplementation Factor (
Targeted Deletion of the Murine apobec-1
http://mcb.asm.org/content/25/16/7260




This article cites 33 articles, 25 of which can be accessed free
CONTENT ALERTS
 more»articles cite this article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new
http://journals.asm.org/site/misc/reprints.xhtmlInformation about commercial reprint orders: 
http://journals.asm.org/site/subscriptions/To subscribe to to another ASM Journal go to: 
 o
n
 January 6, 2014 by W










 January 6, 2014 by W








MOLECULAR AND CELLULAR BIOLOGY, Aug. 2005, p. 7260–7269 Vol. 25, No. 16
0270-7306/05/$08.000 doi:10.1128/MCB.25.16.7260–7269.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Targeted Deletion of the Murine apobec-1 Complementation Factor
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apobec-1 complementation factor (ACF) is an hnRNP family member which functions as the obligate RNA
binding subunit of the core enzyme mediating C-to-U editing of the nuclear apolipoprotein B (apoB) transcript.
ACF binds to both apoB RNA and apobec-1, the catalytic cytidine deaminase, which then results in site-specific
posttranscriptional editing of apoB mRNA. Targeted deletion of apobec1 eliminates C-to-U editing of apoB
mRNA but is otherwise well tolerated. However, the functions and potential targets of ACF beyond apoB mRNA
editing are unknown. Here we report the results of generating acf knockout mice using homologous recombi-
nation. While heterozygous acf/ mice were apparently healthy and fertile, no viable acf/ mice were
identified. Mutant acf/ embryos were detectable only until the blastocyst (embryonic day 3.5 [E3.5]) stage.
No acf/ blastocysts were detectable following implantation at E4.5, and isolated acf/ blastocysts failed to
proliferate in vitro. Small interfering RNA knockdown of ACF in either rat (apobec-1-expressing) or human
(apobec-1-deficient) hepatoma cells decreased ACF protein expression and induced a commensurate increase
in apoptosis. Taken together, these data suggest that ACF plays a crucial role, which is independent of apobec-1
expression, in cell survival, particularly during early embryonic development.
RNA editing is an important genetic adaptation that permits
distinct gene products to be encoded from a single genomic
template. One of the most extensively studied examples of this
model of mammalian gene regulation is substitutional C-to-U
RNA editing of the apolipoprotein B (apoB) transcript, in
which a single nucleotide modification results in the transla-
tional termination of a truncated protein, apoB48, which is
required for intestinal lipid absorption (4). C-to-U editing of
the nuclear apoB mRNA is a site-specific deamination reaction
that requires a holoenzyme containing a minimal functional
core composed of apobec-1, the catalytic deaminase (29), and
an RNA binding subunit, apobec-1 complementation factor
(ACF) (16, 19). These two proteins interact with one another
(16, 19) and also with the substrate apoB RNA (5, 17) in a
manner that positions the targeted C residue in an optimal
configuration with respect to the active site of the deaminase.
Their functional importance and the factors that modulate
their respective abundances and subcellular (17) trafficking
have been the focus of considerable attention (16, 19, 33).
Studies using recombinant protein and cell extracts have
demonstrated that, while necessary for RNA editing, apobec-1
alone is insufficient (23, 26). The requisite importance of apo-
bec-1 was unequivocally revealed through targeted deletion of
apobec1, which completely eliminated in vivo C-to-U editing of
the murine apoB transcript, demonstrating that apobec-1 is an
essential and nonredundant component of the holoenzyme
(20, 21). Nevertheless, while essential for C-to-U RNA editing,
apobec-1 alone is insufficient. In vitro studies using recombi-
nant apobec-1 and ACF have demonstrated that an optimal
stoichiometry exists between these two proteins, each of which
interacts with one another and with the apoB RNA, notably at
a stretch of AU-rich residues flanking the targeted cytidine.
Recent work has identified the major functional domains (in-
cluding three canonical RNA recognition motifs) within ACF
that mediate both protein-protein and protein-RNA interac-
tion and that both facilitate and constrain C-to-U RNA editing
of the nuclear apoB transcript (5, 17). In addition, ACF con-
tains a novel nuclear localization sequence that directs the
importation of heterologous proteins (6). However, while
these findings illustrate the range of biochemical mechanisms
underlying the role of ACF in apoB RNA editing in vitro, there
is little information concerning the requirement for ACF in in
vivo RNA editing or the range of alternative or complementary
targets, either protein or RNA or both.
In the current study, we have undertaken the targeted dele-
tion of the murine acf gene in order to establish the require-
ment for ACF in C-to-U editing of apoB RNA. Our results
from this characterization suggest that ACF has a wider range
of targets than apoB RNA alone.
MATERIALS AND METHODS
Generation of acf/ mice. A genomic bacterial artificial chromosome (BAC)
clone was obtained by screening a 129/SvJ genomic BAC library (Incyte Genom-
ics) with a full-length mouse ACF cDNA. To replace the exon 2 containing the
initiator ATG of ACF with the coding sequence of green fluorescent protein
(GFP) and a phosphoglycerol kinase (PGK)-neomycin (Neo) cassette, a replace-
ment-type targeting vector was engineered. To create the 5 arm, a fragment
containing 2.4 kb of DNA upstream of the translation initiation ATG was
amplified by PCR with the BAC clone as the template. The GFP “knock-in”
cassette was generated by overlapping PCR with the 5 arm and a GFP amplicon
as the templates. The 3-kb 3 arm was generated by PCR, also with the BAC
clone as the template. Both PCR products, i.e., 5 arm-GFP and the 3 arm, were
subcloned into pGEMT-easy (Promega). Upon digestion with NotI, ApaI, and
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XmnI, the 3 arm was inserted into the NotI/ApaI sites of p1339 (accession
number AF335420; a gift from Tim Ley, Washington University) using restriction
sites introduced by PCR. The 5 arm-GFP cassette was added to the KpnI/
BamHI sites of the p1339-3 arm vector upstream of a PGK-Neo cassette. The
targeting construct was linearized with ApaI and electroporated into 129/SvJ
embryonic stem (ES) cells. Genomic DNA was isolated from G418-resistant
colonies, and correctly targeted clones were identified by Southern blot analysis.
Genotyping analysis. The genotype of ES cells was determined by Southern
blotting. Genomic DNA was digested with XbaI, resolved on a 0.8% agarose gel,
transferred to a nylon membrane, and hybridized with a 32P-labeled 793-nucle-
otide (nt) probe corresponding to the sequence downstream of the 3 arm. Over
140 clones were analyzed for the homologous recombination event. A single
positive clone was identified in which a 6.2-kb band was detected in addition to
the 8-kb wild-type band. Targeted clones were expanded in culture, and 200
blastocysts were injected into pseudopregnant recipient C57BL/6 mice. A total of
three chimeras were obtained, from which two mice were selected for breeding
to establish germ line transmission of the targeted allele. The acf genotypes were
determined by PCR with two different sets of three primers (see Fig. 2A). Set 1
included the following: a sense primer (Sse1), FSPmBAC (5-CTGAACTGGG
AATGAGTGGACATG-3), was designed from intron 1 to amplify the wild-type
and targeted alleles; an antisense primer (ASse1a), mACF Ex2 (5-CCCCGGA
TTTGTGATTTGATT-3), based on exon 2, will amplify a 338-bp band; and a
third primer (ASse1b), GFP90AS (5-CACGCTGAACTTGTGGCCGTTTAC
3), corresponding to the GFP sequence, will amplify the targeted allele, pro-
ducing a 408-bp band. Set 2 included the following: the sense primer (Sse2a),
FwdEx2 (5-ATGGAATCAAATCACAAATCCGGGGATGG-3), designed
from the exon 2, amplifies the wild-type allele producing a 610-bp band; the
antisense primer (ASse2), DwnEx2 (5-CTTTCAAAGGTCTAACATGGGCA
GAAGTTG-3), will amplify both wild-type and targeted alleles; and the third
primer (Sse2b), PGK (5-AGGTGGCGCGAAGGGGCCACCAAAGAACGG-
3), corresponding to the PGK sequence of the Neo cassette, will amplify the
targeted allele generating a 230-bp product. acf/ mice were mated and mon-
itored daily for plugs. Embryos at the indicated timed intervals (days postcoitum
[dpc]) were recovered by microdissection for histological analysis or genomic
DNA extraction with a Puregene DNA purification kit (Gentra Systems) and
genotyping as described above.
Protein and RNA extraction and analysis. Tissues were flash frozen in liquid
nitrogen and stored at 80°C until used. Protein concentrations were deter-
mined (Bio-Rad protein assay) on tissue extracts prior to Western blotting. RNA
was isolated using TRIzol (Invitrogen) and 2 g of DNase-treated RNA used for
primer extension analysis of apoB RNA editing and quantitative and semiquan-
titative reverse transcription (RT)-PCR analysis (7). Real-time quantitative
PCRs were performed with an ABI Prism7000 instrument (Applied Biosystems)
by use of SYBR Green Master Mix according to the manufacturer’s instructions,
and mRNA abundance was determined by normalization to the glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) level in each sample. PCR primers were
as follows: ACF (5-GCCAGAATCCTGCAATCCA-3 and 5-AGCATACCTC
TTCGCTTCATCC-3) and GAPDH (5-TGTGTCCGTCGTGGATCTGA-3
and 5-CCTGCTTCACCACCTTCTTGA-3). The distribution of ACF mRNA
in mouse tissues was assessed by semiquantitative RT-PCR amplification using
the following primers: ACF Fwd Ex2 (5-ATGGAATCAAATCACAATCCGG
GGATGG-3) and antisenseEx7 (5-CTGGCAGCAGCCTCCGCCTAGCCAT
GGCGG-3). To improve the detection of spliced variants in the tissue survey,
PCR was performed using [-32P]dCTP (3,000 Ci/mmol, 3 Ci/reaction, NEN)
as previously described (14). The primers were VBACF17 (5-CAGCAATTCC
CAGTCTTCATTTCC-3) and VBACF18 (5-CCCAGGTAAAATGTCATAG
AGTTTG-3). The PCR products were resolved on an 8% polyacrylamide gel
electrophoresis (PAGE) gel and analyzed by phosphorimaging. For analysis of
promiscuous hyperediting of apoB RNA, a 317-bp sequence of apoB RNA was
amplified using primers ND1 (5-ATCTGACTGGGAGAGACAAGTAGC-3)
and mLiver hypered.rev (5-CAACAAATAAATAGAGATTATGG-3). The
PCR products were subcloned into PCR-Script (Stratagene) according to the
manufacturer’s protocol. Ten clones were randomly selected for plasmid DNA
isolation and sequencing using an automated sequencer and T3 primer.
siRNA silencing of ACF. Small interfering (siRNA) oligonucleotides were
selected following established parameters (11), and several candidate primers,
both murine and human specific, were purchased from Dharmacon Research
Inc. Rat hepatoma cells (McArdle7777; American Type Culture Collection), a
rodent cell line known to express ACF (7, 32), and human hepatoma cells
(HepG2) were grown to 40% confluence on coverslips and transfected with 100
nM ACF or control-scrambled siRNA oligonucleotides according to the manu-
facturer’s instructions (Ambion). Forty-eight hours posttransfection, cells were
fixed in 10% formalin (Sigma) and probed with a rabbit anti-caspase 3 (active
form) antibody (Cell Signaling) followed by a probe with Cy3 secondary antibody
(Jackson Immunoresearch). The nuclei were identified using 4,6-diamidino-2-
phenylindole (DAPI) (1 mg/ml in phosphate-buffered saline). Silencing of ACF
protein expression was also assessed by Western blotting of cell lysates from
siRNA or scrambled oligonucleotide-transfected cells grown under identical
conditions with a rabbit polyclonal ACF antibody (7).
RESULTS AND DISCUSSION
Murine acf gene structure. The murine acf gene contains 15
exons with the known functional domains illustrated in Fig. 1A.
These findings are generally in agreement with the recent
findings of Dur and colleagues (10), with the exception that
there are three noncoding exons (exons 5, 6, and 11) reported
in the current report (Fig. 1A). The two major protein prod-
ucts (ACF64 and ACF65) differ, as in humans, by the differ-
ential splicing of a single exon (Fig. 1A), which results in an
eight-amino-acid insertion in the larger protein. A similar pat-
tern of alternative splicing was demonstrated in the human
ACF gene (14). ACF mRNA expression, as determined by
real-time quantitative PCR, was distributed predominantly in
the adult liver, small intestine, and kidney (data not shown).
This pattern confirms that reported by Dur and colleagues
(10). Recombinant human ACF64 and ACF65 reveal indistin-
guishable biochemical activities (5), but the possibility of an
alternative biological function for these isoforms cannot be
excluded. ACF43, a splice variant recently described in the rat
(26), appears to be a minor transcript (1%) in murine tissues
(data not shown). ACF mRNA and protein were detected at 12
days of mouse embryonic development (Fig. 1B and C). ACF
immunostaining was readily detected in the embryonic day 12
(E12) developing heart, spinal cord, and lung tissues (Fig. 1D),
in which there is virtually no detectable ACF mRNA or protein
in adults (data not shown).
acf gene targeting and phenotype characterization following
heterozygous deletion. A replacement-type targeting construct
(see Materials and Methods) (Fig. 2A) was electroporated,
and ES cells were screened by Southern blotting (Fig. 2B).
acf/ ES cells were injected into wild-type blastocysts to cre-
ate germ line acf/ mice. PCR genotyping (Fig. 2C) was
performed to identify mutant mice. acf/ mice appeared
healthy, grew at a rate similar to wild-type mice, and were
fertile. ACF protein content was reduced in the kidney, liver,
and small intestine of acf/ mice relative to that found in
wild-type littermates (Fig. 3A).
ACF and apobec-1 interaction yields an enzyme complex
whose activity is critically dependent on the stoichiometry of its
minimal component subunits (2, 7). To determine the func-
tional consequence of the aforementioned alterations in ACF
protein content, we examined the C-to-U editing of endoge-
nous apoB mRNA; the findings demonstrate a consistent and
statistically significant increase in the proportions of U6666-
containing transcripts in both liver and kidney (Fig. 3B). apoB
mRNA editing was unchanged in the small intestines of these
animals, exceeding 95% in both wild-type and acf/ mice
(Fig. 3B). The demonstration of increased apoB mRNA edit-
ing in liver and kidney, by contrast, was somewhat unexpected
and suggests that heterozygous deletion of ACF alters the
stoichiometry of the core components of the holoenzyme.
Among the possible considerations in this scenario are alter-
ations in a metabolically active nuclear ACF pool, changes in
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nuclear cytoplasmic shuttling of apobec-1 and/or ACF (9), or
even changes in ACF interaction with other protein partners.
These possibilities will of course require formal evaluation in
future studies.
In order to determine whether the increased C-to-U editing
activity in acf/ liver was confined to the canonical site at nt
6666, 10 clones were randomly selected from RT-PCR prod-
ucts, and a total of over 3,100 nt sequences was obtained from
a region containing eight C residues, including the canonical
site (Fig. 3C). The results reveal only one clone (Fig. 3C) in
which there was an additional edited C, suggesting that pro-
miscuous editing (25) or hyperediting (31) was not taking place
in the setting of increased C-to-U editing at nt 6666. The
C-to-U editing of other RNA targets was not examined. Taken
together, the functional outcome of the heterozygous targeting
of murine acf points to a tissue-specific increase in endogenous
apoB RNA editing activity, possibly reflecting a subtle but
distinct alteration in the stoichiometry of the core editing com-
plex.
Phenotype associated with homozygous deletion of murine
acf. Three separate lines of acf/ mice were established from
independent founders, two of which were littermates and one
of which was from a separate breeding. The progeny were
genotyped by PCR (Table 1). We detected no acf/ mice
from any of these lines after genotyping 42 litters and 332
offspring, indicating that disruption of the acf locus resulted in
embryonic lethality. The litter sizes from these heterozygous
matings were similar to those from wild-type littermates
(range, 7 to 10), and there was no apparent gender bias. In
addition to the absence of homozygous acf/ offspring, we
FIG. 1. Genomic organization of the mouse acf gene. (A) Upper panel, schematic representation of the intron-exon junctions. Solid bars
represent exons. Solid lines represent introns. The exons encoding the three RNA recognition motifs are indicated by brackets. Lower panel,
splicing pattern of mouse acf gene. (B) Tissue-specific expression of ACF in wild-type mouse embryos. ACF mRNA was extracted from E12.5
embryos and amplified by RT-PCR. The PCR products were resolved on a 1.2% agarose gel and visualized with ethidium bromide. As a positive
control, mouse GAPDH RNA was amplified. A negative control performed without reverse transcription is shown (RT). (C) Protein expression
in wild-type embryo. Crude extracts from E12.5 embryos were resolved on a 10% sodium dodecyl sulfate-PAGE gel, transferred to membrane, and
probed with antiserum to ACF. (D) ACF expression in an E12.5 embryo. Whole-mount immunostaining of a wild-type embryo at E12.5 with
antisera to ACF. Note the staining in heart, lung, and spinal cord. A negative staining performed without primary antibody is shown for each tissue
(lower panels).
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observed a significant increase in heterozygous offspring
among all three lines, with the ratio of heterozygous to wild-
type mice averaging 10:1 (range, 8.3 to 12.6) (Table 2), in-
stead of the 2:1 ratio predicted from Mendelian inheritance.
These genotypes were confirmed by two independent primer
sets, as detailed in Fig. 2C, suggesting that trivial explanations,
such as genotyping errors, are unlikely to account for the
apparent increase in the number of heterozygous offspring. In
FIG. 2. Targeted disruption of acf gene. (A) Mouse acf gene and targeting vector. Upon homologous recombination of the 5 and 3 arms of the
targeting vector with the acf locus (top), the exon 2 is replaced by the coding sequence of GFP and a LoxP-flanked Neo cassette. (B) Southern blot analysis
of genomic DNA isolated from recombinant ES cells. Upon digestion with XbaI, the wild-type (/) allele gives rise to a 8-kb fragment, while the
digestion of the mutant allele (/) generates 8- and 6.2-kb fragments, detected with a 3 probe (hashed box). (C) PCR genotyping of wild-type and
heterozygous mutant mice. Primers Sse1, ASse1a, and Asse1b, indicated in blue, were mixed in a single PCR and used to amplify a 338-bp product
corresponding to the wild-type (/) and a 408-bp product associated with the targeted allele (/), lanes 1 and 2. Similarly, primers Sse2a, Sse2b, and
ASse2, indicated in green, amplified a 610-bp wild-type band (lane 3) and a 230-bp band corresponding to the targeted allele (lane 4).
FIG. 3. Endogenous apoB mRNA editing in wild-type and acf/mice. (A) Immunodetection of ACF protein in liver, small intestine (SI), and
kidney isolated from wild-type or heterozygous mice. Equal amounts of protein were resolved by sodium dodecyl sulfate-PAGE and probed with
antisera to ACF, Hsp40, and GFP. (B) apoB mRNA editing of acf/ and wild-type mice. Upper panel, apoB mRNA editing was determined by
primer extension. The relative mobility of the unedited (C) and edited (U) products is indicated on the left. Lower panel, bar graph representing
the data (mean  standard deviation; n 	 4) for each group. Statistically significant differences between groups are indicated by asterisks.
(C) Promiscuous editing of hepatic apoB mRNA in acf/ mice. A schematic representation of cytidine residues promiscuously targeted (31) is
shown. A 350-bp fragment of apoB mRNA was amplified by RT-PCR, subcloned into pPCR-Script vector, and sequenced. Ten clones from two
acf/ mice were analyzed. Nine clones exhibit a uridine residue at the canonical site 6666; only one clone (clone 8) shows an additional C-to-U
change at position 6762. Note that a reduction of the ACF protein level does not make the apoB mRNA more susceptible to promiscuous editing.
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addition, further crosses of the heterozygous acf/ (mixed
background 129/SvJ 
 C57BL/6) into an acf wild-type
C57BL/6 apobec1/ line resulted in two litters containing a
total of 12 mice, all of which were acf/ (data not shown). The
karyotype of the targeted ES cells revealed a normal 40 X,Y
distribution, suggesting that there is no chromosomal duplica-
tion or major rearrangement occurring in the ES cells used to
generate the lines. To our knowledge, there are no other ex-
amples of an embryonic lethal phenotype where the distribu-
tion of genotypes favors the heterozygosity of the candidate
gene, but further dissection of the underlying mechanisms will
clearly require additional investigation.
To determine the stage at which homozygous mutant mice
die, we analyzed embryos at different times of gestation. Geno-
typing of embryos dissected at E7.5 and E12.5 revealed no
acf/ mice (Table 1). Furthermore, histological examination
of the implantation sites (n	 6) in uterine sections obtained at
E6.5 and E7.5 failed to reveal evidence of thrombi at the
positions of putative resorbed deciduae (data not shown). In
addition and as expected, no empty deciduae were noted under
conditions where all implanted embryos (wild-type and het-
erozygous acf/) appeared normal (data not shown). Taken
together, these observations suggest that premature death of
implanted acf/ embryos was unlikely to account for the lack
of acf/ mice. We also attempted to recover improperly im-
planted embryos at E4.5 by flushing the uteri of pregnant
acf/ animals but failed to obtain any material. Taken to-
gether, these findings point to an early implantation defect in
the acf/ embryos.
To further investigate the possibility that acf/ embryos fail
to implant, we genotyped 42 blastocysts recovered from the
uteri of timed pregnant acf/ mice at E3.5, a period selected
to closely precede implantation. The genotype distribution
(Table 1) revealed that 9 were acf/, 6 were wild type, and 27
were heterozygous acf/. These results indicate that homozy-
gous acf/ embryos almost certainly fail to implant.
Among the mechanisms we considered for the failure of
acf/ embryos to implant was an inability to develop properly
to the stage where implantation can occur. To assess this pos-
sibility, blastocysts (E3.5) were harvested from heterozygous
acf/ mice, cultured for 4 to 7 days, and examined for their
ability to develop blastocyst outgrowths (27). The outgrowths
were then genotyped by PCR. From 62 cultures, 40 blastocysts
remained attached and revealed histological evidence of pro-
liferation of both trophoblasts and inner cell masses (8, 28)
(data not shown). Genotype analysis of these 40 outgrowths
revealed that 22 were wild type and 18 were heterozygous
acf/. However, no acf/ outgrowths were detected, consis-
tent with the suggestion that acf/ blastocysts degenerate and
undergo cell death within the first 4 days of culture. These
findings collectively point to the possibility that ACF is re-
quired for preimplantation development.
ACF knockdown in somatic cells results in apoptotic death.
To investigate the possibility that ACF is required for cell
survival, we undertook ACF knockdown using siRNA-medi-
ated gene silencing. Rat hepatoma cells were transfected with
candidate siRNAs targeting different regions of ACF mRNA
(Fig. 4A). ACF protein abundance was reduced by70%, with
siRNAs targeting regions located 316 and 823 nucleotides
downstream of the initiator ATG, whereas no effect was ob-
served when cells were transfected with scrambled siRNAs
(Fig. 4A). In the setting of ACF knockdown, we observed an
increased number of apoptotic cells, as indicated by the num-
ber of caspase 3-positive nuclei detected in siRNA4-treated
cells (Fig. 4B and D). The initiation of apoptosis was supported
by the demonstration of cleavage of caspase 3 into its active
form (Fig. 4C). The induction of apoptosis was further ana-
lyzed by staining with terminal deoxynucleotidyltransferase-
mediated dUTP-biotin nick end labeling. The delivery of
siRNA4 to rat hepatoma cells resulted in a significant, approx-
TABLE 1. Numbers of wild-type, heterozygous, and homozygous
null offspring from genotype analysis of progeny from m acf
heterozygous intercrosses
Age (dpc)
No. with ACF genotypea
Total
/ / /
Weaned 31 301 0 332
12.5 3 14 0 17
7.5 1 16 0 17
3.5 6 27 9 42
a /, wild type; /, heterozygous; /, homozygous.
TABLE 2. Details of wild-type and heterozygous acf genotype
distribution in each individual line from genotype analysis of




genotypeb het/wtc No. of litters
/ /
1 13 164 12.6 22
2 14 117 8.3 16
3 0 20 NA 4
a Asterisks indicate lines that were established from two littermate founders.
b /, wild type; /, heterozygous.
c het/wt, heterozygous/wild-type ratio; NA, not applicable.
FIG. 4. Silencing of ACF mRNA in McArdle7777 cells. (A) McArdle7777 cells were transfected with individual siRNAs targeting two distinct
regions of ACF mRNA. siRNA2 targets a sequence located 316 nt downstream of the transcription initiation codon. siRNA4 recognizes a motif
located 823 nt from the ATG. A scrambled siRNA (Sc) was used as negative control. Protein lysates were prepared at 48 h posttransfection, and
the ACF level was analyzed by Western blotting using antiserum to ACF. Hsp40 probing was used as the control for equal loading.
(B) McArdle7777 cells were transfected with a scrambled siRNA or with siRNA4. At 48 h after transfection, cells were analyzed by immunocy-
tochemistry. For each assay, five fields were analyzed for caspase 3-positive nuclei. The data are representative of three independent experiments.
(C) Protein lysates were prepared from McArdle7777 cells transfected with scrambled siRNA or siRNA4. The induction of an apoptotic cascade
was analyzed by Western blotting which probed for the active form of caspase 3. An additional control was performed with untreated cells (C).
(D) Immunofluorescence microscopy of McArdle7777 cells treated with a scrambled siRNA or siRNA4. Apoptotic cells were characterized by the
presence of the active form of caspase 3.
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imately threefold increase of the number of nuclei positive by
terminal deoxynucleotidyltransferase-mediated dUTP-biotin
nick end labeling (23%) compared to the number in the
scrambled siRNA-treated cells (8%). The induction of apo-
ptosis in rat hepatoma cells was also replicated in experiments
using siRNA knockdown of ACF in primary murine hepato-
cytes (data not shown).
One potential caveat to the conclusions concerning the ef-
fects of siRNA-mediated knockdown of ACF expression is that
both rat hepatoma cells and murine hepatocytes express both
ACF and apobec-1. Since the unconstrained expression of apo-
bec-1 has been shown to be associated with alterations in
cellular mRNA stability (1, 3), DNA mutator activity (13, 22),
and even altered growth and malignant transformation (3, 30),
it was important to extend the findings of siRNA-mediated
knockdown of ACF to cells in which no apobec-1 expression is
detected. Accordingly, we turned to the human hepatoma
HepG2 cell line, since human liver is a robust source of apoB
RNA-editing complementation activity and of ACF expression
but does not express apobec-1 (12). siRNA-mediated knock-
down of ACF expression in HepG2 cells resulted in an 76%
(four independent assays) decrease in ACF protein expression
(Fig. 5A) and a 30-fold increase in caspase 3-positive-stain-
ing nuclei (Fig. 5B). These results reinforce the conclusion that
ACF knockdown in somatic cells results in apoptosis. In addi-
tion, the findings in HepG2 cells strongly imply that this effect
is independent of apobec-1 expression.
To further resolve the observed embryonic lethality associ-
ated with homozygous acf deletion in vivo, we endeavored to
determine the exact timing and cell type in which apoptosis
occurs in E3.5 blastocysts. However, as inferred from immu-
nofluorescent staining, ACF expression was below the level of
detection in blastocysts isolated from heterozygous acf mat-
ings, precluding a formal conclusion to the question of whether
apoptosis occurs exclusively in acf null blastocysts (data not
shown). In addition, the transfection of siRNA oligonucleo-
tides into cultured acf/ ES cells produced inconsistent ef-
fects concerning the number of dead and apoptotic cells, which
were possibly the result of uncontrolled variations in transfec-
tion efficiency (data not shown). We suspect that the resolution
of the mechanisms and pathways leading to apoptosis following
targeted acf deletion will require the development of a condi-
tional deletor line.
Summary conclusions. The central finding of this report is
that the homozygous deletion of murine acf is associated with
embryonic lethality, most likely the result of a developmental
defect in blastocyst growth, leading to preimplantation failure.
What functional properties of ACF could account for this
phenotype? Crucial to its role in catalyzing C-to-U RNA ed-
iting is the fact that ACF is an RNA binding protein with high
affinity (low kd) for AU-rich RNAs, including apoB RNA, its
presumed target (7, 17, 18). In this regard, it is relevant that
several AU-rich RNAs, including those for interleukin-6, in-
terleukin-1, Cox2, and gamma interferon, are all expressed in
the early stages of embryonic development, including the blas-
tocyst stage (24). Although the binding of ACF to these targets
has yet to be demonstrated, it is not unreasonable to speculate
that altered binding of ACF to any of these or other AU-rich
targets might interrupt the development of acf/ embryos.
Probing these underlying mechanisms will require alternative
approaches to bypass the early lethality associated with germ
line deletion. A potentially important clue to the mechanisms
involved in the early embryonic lethality has emerged from
recent findings by Kinnaird and colleagues (15). These workers
have demonstrated that RNA interference-mediated silencing
of the Caenorhabditis elegans ACF homolog, HRP-2, leads to
embryonic arrest, with 48 h of exposure resulting in a failure to
progress beyond the 64-cell stage (15). These findings, consid-
ered together with the current data, suggest that ACF is an
hnRNP family member with a conserved and nonredundant
role in early embryonic development.
ACKNOWLEDGMENTS
This work was supported by grants (HL-38180, DK-56260, and DK-
52574) to N.O.D.
We acknowledge the technical assistance of Karen Hutton in the
Morphology Core and Ted Simon and Jennifer Stratman in the Mouse
Core of the Washington University DDRCC.
FIG. 5. Silencing of ACF in human hepatoma HepG2 cells.
(A) Representative Western blot of ACF protein expression in extracts
prepared from HepG2 cells transfected with a human ACF-specific
siRNA or a scrambled siRNA control. The Hsp40 signal was used to
demonstrate equal protein loading. (B) Quantitative representation of
apoptotic cells upon treatment with a scrambled or an ACF-specific
siRNA. At 48 h after transfection, HepG2 cells were fixed and stained
for caspase 3 (data are means  standard errors of the means; the
asterisk indicates a P value of 0.0002). C, control.
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